Want to see HK:1061 full AI Analyst Report?
1061 Stock Chart & Stats
HK$2.51
-HK$0.03(-1.21%)
At close: 4:00 PM EDT
HK$2.51
-HK$0.03(-1.21%)
Day’s Range― - ―
52-Week RangeHK$2.37 - HK$6.12
Previous CloseN/A
Volume51.00K
Average Volume (3M)863.25K
Market Cap
HK$1.38B
Enterprise ValueHK$1.70K
Total Cash (Recent Filing)HK$784.14M
Total Debt (Recent Filing)HK$346.90M
Price to Earnings (P/E)4.4
Beta0.51
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.74%
Share Statistics
EPS (TTM)0.56
Shares Outstanding567,006,000
10 Day Avg. Volume975,600
30 Day Avg. Volume863,250
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)0.89
Price to Sales (P/S)1.18
P/FCF Ratio16.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.57
Revenue Forecast (FY)HK$1.87B
Bulls Say, Bears Say
Bulls Say
High And Stable MarginsExceptionally high gross margins and solid EBIT margins indicate durable product-level economics and pricing power typical of specialized biologics. These margins provide a long-term cushion against revenue variability and fund reinvestment, R&D, and shareholder returns even through moderate cyclical downturns.
Improving Balance Sheet LeverageA materially lower debt-to-equity ratio signals stronger financial flexibility and lower solvency risk. Improved leverage expands capacity for targeted capex, product launches, or selective partnerships without over-reliance on external funding, supporting multi-month strategic initiatives and resilience to shocks.
Proprietary Niche Product FocusA focused portfolio of proprietary bFGF-based biologics creates defensible competitive advantages: specialized clinical indications, regulatory know-how, and manufacturing expertise. This niche orientation supports stable clinical adoption and pricing power over time versus commodity drug segments.
Bears Say
Volatile Free Cash FlowLarge swings and a steep FCF decline reduce predictability of internal funding for capex, marketing, and dividends. Persistent volatility can force external financing or cutbacks, undermining strategic execution and the company’s ability to sustain growth initiatives over the medium term.
Choppy Revenue MomentumIntermittent declines and recoveries in revenue complicate long-term capacity planning and reduce visibility on sustainable growth. This uneven top-line trend can limit operating leverage, strain go-to-market investments, and signal competitive or market-access headwinds that persist beyond short-term cycles.
Geographic Concentration RiskHeavy reliance on Greater China concentrates exposure to regional regulatory, reimbursement, and demand shifts. This lack of geographic diversification raises structural execution and policy risk, potentially affecting sales and margins across multiple quarters if regional conditions deteriorate.
Essex Bio-Technology News
1061 FAQ
What was Essex Bio-Technology Limited’s price range in the past 12 months?
Essex Bio-Technology Limited lowest stock price was HK$2.37 and its highest was HK$6.12 in the past 12 months.
What is Essex Bio-Technology Limited’s market cap?
Essex Bio-Technology Limited’s market cap is HK$1.38B.
When is Essex Bio-Technology Limited’s upcoming earnings report date?
Essex Bio-Technology Limited’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Essex Bio-Technology Limited’s earnings last quarter?
Essex Bio-Technology Limited released its earnings results on Mar 23, 2026. The company reported HK$0.273 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.273.
Is Essex Bio-Technology Limited overvalued?
According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Overvalued.
Does Essex Bio-Technology Limited pay dividends?
Essex Bio-Technology Limited pays a Semiannually dividend of HK$0.07 which represents an annual dividend yield of 5.74%. See more information on Essex Bio-Technology Limited dividends here
What is Essex Bio-Technology Limited’s EPS estimate?
Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Essex Bio-Technology Limited have?
Essex Bio-Technology Limited has 567,006,000 shares outstanding.
What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?
Essex Bio-Technology Limited reported an EPS of HK$0.273 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.013%.
Which hedge fund is a major shareholder of Essex Bio-Technology Limited?
Currently, no hedge funds are holding shares in HK:1061
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Essex Bio-Technology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.30%
12-Months-Change
Fundamentals
Return on Equity
5.74%
Trailing 12-Months
Asset Growth
17.02%
Trailing 12-Months
Company Description
Essex Bio-Technology Limited
Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.
Technical Analysis
Hua Medicine
―
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―